Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | CCR3 | P51677 | 2/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5102678 | 0.81 | TDP1 (0.39) | GPR119ADRB2CCR3HRH1GRIN1 | |
| Hydrochloric Acid SCHEMBL5655886 | 0.79 | DRD4 (0.58) | L3MBTL1ADRB2CCR3SIGMAR1 | |
| SCHEMBL5098799 | 0.78 | CCR3 (0.48) | CCR3HRH1GRIN1GRIN2BHRH3 | |
| SCHEMBL5099023 | 0.75 | HRH3 (0.44) | ADRB2CCR3HRH1GRIN1GRIN2B | |
| SCHEMBL5102691 | 0.74 | HRH3 (0.50) | CCR3HRH1GRIN1GRIN2BHRH3 | |
| SCHEMBL5658226 | 0.74 | DRD2 (0.49) | GPR119CCR3HRH1HRH3 | |
| SCHEMBL5102255 | 0.73 | CARM1 (0.65) | HRH3SIGMAR1 | |
| SCHEMBL5109440 | 0.73 | CCR3 (0.45) | CCR3HRH1GRIN1GRIN2BHRH3 | |
| SCHEMBL10077964 | 0.72 | HRH3 (0.54) | CCR3HRH1HRH3PTGS1PTGS2 | |
| SCHEMBL5655665 | 0.71 | POLB (0.44) | ADRB2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7304077-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-12-04 | — | — | US | disclosed |
| US-20040102432-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2004-05-27 | — | — | US | disclosed |
| EP-1322611-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002020484-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2002-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102432-A1 | Chemical compounds | CCL11, HRH1, HRH4 | L3MBTL1 4858/4885GPR119 354/4885ADRB2 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.